HCW&Co publishes Prana Reach2HD trial report, results “beat expectations”

FEBRUARY 2014: MELBOURNE, Australia and NEW YORK, USA: US-based equity research analyst George B. Zavoico, Managing Director of H.C. Wainwright & Co, has published a report on Prana Biotechnology's (ASX:PBT / NASDAQ:PRAN) Phase 2 trial of PBT2 in patients with Huntington's disease, Reach2HD.

The report can be viewed online here or downloaded here: 14-0218_PRAN-FT_Reach2HD.